{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:22:48Z","timestamp":1772994168836,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ervogastat, a diacylglycerol\u2010O\u2010acyltransferase\u20102 inhibitor, and clesacostat, an acetyl\u2010CoA carboxylase inhibitor, are in clinical development for the treatment of metabolic dysfunction\u2010associated steatohepatitis (MASH). Study 1 and Study 2 were open\u2010label, Phase 1 trials that assessed the pharmacokinetics (PK) of a single dose of ervogastat (100 mg) and clesacostat (25 mg), respectively, in participants (n = 6\/cohort) with mild, moderate, or severe hepatic impairment (HI) and compared to those without HI (reference). Plasma samples were analyzed for both total and unbound concentrations in Study 2 as clesacostat is highly protein bound. In Study 1, compared to participants without HI, ervogastat exposure (AUC\n                    <jats:sub>inf<\/jats:sub>\n                    ) was 56%, 65%, and 52% higher in participants with mild, moderate, and severe HI, respectively. However, when excluding PK data from a participant with unexplained low exposures in reference group, ervogastat exposures were similar between those with\/without HI. In Study 2, total clesacostat exposure was 36%, 24%, and 19% higher for mild, moderate, and severe HI, respectively, as compared to reference group. Unbound clesacostat exposures were 70%, 83%, and 166% higher for mild, moderate, and severe HI cohorts, respectively, with clesacostat plasma protein binding shown to decrease with increasing HI severity. Ervogastat and clesacostat were well tolerated with no clinically significant laboratory abnormalities or changes in vital signs and\/or electrocardiograms observed. Observed exposures in HI studies were consistent with simulated exposures in MASH population. Taking into consideration the safety margins at the highest doses evaluated in Phase 2, no dose adjustment of ervogastat or clesacostat is currently warranted for patients with hepatic impairment.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70106","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:53:58Z","timestamp":1758808438000},"page":"1876-1888","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl\u2010CoA Carboxylase (ACC) Inhibitor"],"prefix":"10.1002","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8638-5751","authenticated-orcid":false,"given":"Manoli","family":"Vourvahis","sequence":"first","affiliation":[{"name":"Pfizer Inc.  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur J.","family":"Bergman","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9703-1644","authenticated-orcid":false,"given":"Adam G.","family":"Ogden","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-5805","authenticated-orcid":false,"given":"Jim","family":"Hughes","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1344-2233","authenticated-orcid":false,"given":"James R.","family":"Gosset","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9701-756X","authenticated-orcid":false,"given":"Amit S.","family":"Kalgutkar","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-4683","authenticated-orcid":false,"given":"Neeta B.","family":"Amin","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Cambridge MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1503519"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0239"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535\u2010021\u201001796\u2010x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249646"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419\u2010020\u201003003\u2010w"},{"issue":"4","key":"e_1_2_10_7_1","first-page":"631","article-title":"Evaluation of fatty acid metabolism\u2010related gene expression in nonalcoholic fatty liver disease","volume":"16","author":"Nakamuta M","year":"2005","journal-title":"Int J Mol Med"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001489\u20101"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15593"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.07.009"},{"issue":"1","key":"e_1_2_10_11_1","article-title":"Diacylglycerol acyltransferase 2 (DGAT2) inhibitor PF\u201006865571 reduces liver fat by MRI\u2010PDFF after 2 weeks in adults with NAFLD [abstract]","volume":"70","author":"Saxena AR Chidsey K","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.12.008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.782"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2022.2062487"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01200"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13687"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00640"},{"key":"e_1_2_10_18_1","unstructured":"FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design Data Analysis and Impact on Dosing and Labeling. May2003.https:\/\/www.fda.gov\/media\/71311\/download"},{"key":"e_1_2_10_19_1","first-page":"924","article-title":"Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy\u2010confirmed metabolic dysfunction\u2010associated steatohepatitis (MASH) and F2\u2010F3 fibrosis: results from the phase 2, randomized, double\u2010blind MIRNA study","volume":"10","author":"Wong VW","year":"2025","journal-title":"Lancet Gastro Hep"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13275"},{"key":"e_1_2_10_21_1","volume-title":"NONMEM user's guides (1989\u20102009)","author":"Beal SL SL","year":"2009"},{"key":"e_1_2_10_22_1","volume-title":"R: A language and environment for statistical computing. Version 4.3.1","year":"2023"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2125"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3643"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3062"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1695"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2829"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2105"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010024\u201001420\u20100"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2427"},{"key":"e_1_2_10_31_1","unstructured":"FDA Briefing Document \u2010 NDA# 212833 Obeticholic Acid (OCA) Gastrointestinal Drugs Advisory Committee (GIDAC) Meeting.2023.www.fda.gov\/media\/168215\/download."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70106","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:07:14Z","timestamp":1772982434000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/jcph.70106"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70106","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-06-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}